Peptide LexiconAll compounds

Vilon (Lys-Glu): The Two-Amino-Acid Bioregulator From St Petersburg — What It Is and What the Research Shows

Vilon is the dipeptide lysyl-glutamic acid (Lys-Glu, KE), one of the short 'peptide bioregulators' from V. Khavinson's St Petersburg programme. Sellers present it for immunity and ageing. Its indexed record is mostly mouse, cell and Russian-language clinical papers from that programme; no randomised trial is registered.

Not approved anywhereNo registered trialSingle-programme evidence base

Caroline S · Published 2026-11-12

Length

2 amino acids — C11H21N3O5, molecular weight 275.30 (PubChem CID 7010502)

Sequence

KE (Lys-Glu)

Origin

Synthetic; the two-residue member of the St Petersburg short-peptide family, described by its developers as 'thymomimetic', a thymus-type signal

Last reviewed

2026-11-12

What is it good for?

Sellers present it as an immune and anti-ageing bioregulator. The indexed research reports, in mice, fewer tumours and longer life; in cultured human and animal cells, changes in chromatin and gene expression; and, in Russian-language clinical reports, changes in blood clotting and immune markers in people with diabetes. None of those reports is a registered randomised trial.

Illustration: Two small, clear glass vials, one with pale green liquid, one with milky white powder, on a white surface.
Illustration

What it is

Vilon is two amino acids: lysine joined to glutamic acid. PubChem's record (CID 7010502) names it (2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]pentanedioic acid — L-lysyl-L-glutamic acid — with the formula C11H21N3O5 and a molecular weight of 275.30. That formula is exactly what a Lys-Glu dipeptide should have (our check against the residue masses).

Its developers, at the St Petersburg Institute of Bioregulation and Gerontology under V. Khavinson, list it among their peptide bioregulators alongside epitalon, thymalin, cartalax, testagen and vesugen, which adds one amino acid to Vilon's two. Papers from that group call Vilon "thymomimetic" — a short synthetic copy of the kind of signal they attribute to thymus extracts.

What the research shows

The indexed record is small and concentrated. A PubMed search on 2026-11-12 returned 62 records with "vilon" in the title or abstract, from 1997 to 2023; one is an unrelated data-network method that happens to be called ViLoN.

Kind of study What was reported Example records
Mice Fewer spontaneous tumours and longer life Khavinson & Anisimov 2000 (PMID 10944717)
Mice, chemical carcinogen Tumours in 14.3% given 10 µg/kg vs 60% of controls Pliss et al. 2005 (PMID 16308980)
Mouse heart Gene-expression changes on DNA microarrays, beside epitalon Anisimov et al. 2002 (Bull Exp Biol Med)
Human cells in culture Chromatin "reactivation" in lymphocytes from old people; thymus-cell and stem-cell gene changes PMIDs 15105581, 23486604, 37782636
Patients Clotting and immune markers in type 1 diabetes; survival and complications in elderly colorectal cancer PMIDs 17152731, 18306698, 16075684

Three things the table does not show. The patient papers are Russian-language reports in the programme's own gerontology journal, and their abstracts give no patient count, no control group and no randomisation; the 2005 cancer paper describes its own findings as "preliminary results." A 2013 review by the programme's authors (PMID 24003726) summarises their clinical experience with several bioregulators, including Vilon — a review of their own work, not an independent one. And no study of Vilon is registered on ClinicalTrials.gov: its single match for the word is an unrelated breast-cancer pathology study (NCT02580799, read 2026-11-12).

What is not established

  • That the mouse results carry over. Fewer tumours and longer life were measured in mice; no study has looked for either outcome in people.
  • What the patient reports actually counted. The diabetes and colorectal-cancer abstracts give no head-count, no control arm and no randomisation, so their marker changes cannot be weighed.
  • What happens to Lys-Glu in the body. Whether it stays a dipeptide or is split into its two amino acids after dosing is not measured in any indexed abstract on people.
  • An outside confirmation. The biological and clinical papers come from the programme and its collaborators, and the main clinical summary is the 2013 review of its own work.

Where it stands

  • Regulatory status: Drugs@FDA and openFDA hold nothing for it, and no paper reports a marketing approval anywhere.
  • Where readers meet it: immune and anti-ageing bioregulator listings and research-peptide shops. Their products are not reviewed in this library.
  • Size of the record (2026-11-12): 62 PubMed hits from 1997 to 2023, mostly mouse and cell work; no registered trial.

The other dipeptide in the same family is Thymogen (Glu-Trp), and the longest-studied member is epitalon, whose record has the same single-programme shape. The thymus extract these short peptides are said to imitate is described in the thymalin entry, and the hormones the thymus really makes are set out in the thymosin entry. For how two amino acids join at all, see the peptide bond entry.

What the research shows

Extends life span and reduces tumours in mice

Khavinson & Anisimov 2000 (PMID 10944717); Pliss et al. 2005 (PMID 16308980): tumours in 14.3% vs 60% of controls after a chemical carcinogen

Changes chromatin and gene activity in human cells

Cultured lymphocytes from old people (PMID 15105581), thymus cells (PMID 23486604), mesenchymal stem cells (PMID 37782636) — laboratory only

Improves blood clotting and immune markers in diabetes

Kuznik et al. 2006 and 2007 (PMIDs 17152731, 18306698), Russian-language reports in Adv Gerontol; abstracts give no patient numbers, randomisation or placebo

Improves survival in elderly cancer patients

Ias'kevich et al. 2005 (PMID 16075684), described by its authors as 'preliminary results'; no numbers in the abstract

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

Approved as a medicine

No approval found: Drugs@FDA and openFDA return nothing for it, and none of the indexed papers reports a marketing approval (2026-11-12).

Published record

PubMed: 62 records with 'vilon' in the title or abstract (1997–2023), one an unrelated network method called ViLoN; ClinicalTrials.gov's single 'vilon' match is an unrelated breast-cancer pathology study (2026-11-12).

Evidence concentration

The biological and clinical papers come from the Khavinson programme and its collaborators.

Frequently asked questions

What is Vilon?

A synthetic dipeptide — lysine joined to glutamic acid, written Lys-Glu or KE. Its St Petersburg developers class it as a thymus-type peptide.

What is Vilon said to be good for?

Sellers present it for immunity and healthy ageing. The research behind those claims is mice, cultured cells and a few Russian-language patient reports from the same programme; none is a registered randomised trial.

Has Vilon been tested in humans?

Only in reports from the originating programme. Indexed abstracts describe patients with type 1 diabetes and elderly colorectal cancer patients given Vilon alongside usual treatment, without patient numbers, a control group or randomisation in the abstract. ClinicalTrials.gov lists no study of it (2026-11-12).

Is Vilon the same as Thymogen?

No. Both are dipeptides from the same school of research and both are described as thymus-type, but Thymogen is Glu-Trp and Vilon is Lys-Glu — different amino acids.

How is Vilon related to epitalon?

They come from the same programme and were studied side by side in several papers, but epitalon is a tetrapeptide (Ala-Glu-Asp-Gly) and Vilon is a dipeptide (Lys-Glu). A 2023 Georgian study tested both, with livagen and cortagen, on cultured lymphocytes from people aged 75 to 88.

Is Vilon approved?

No approval record was found: the US drug databases return nothing for it, and none of the indexed papers reports a marketing approval. It circulates as a research peptide and as a component of bioregulator products.